FASLG and cancer: Consistent with our findings, Hoffmann et al. reported lower sFasL levels in patients with HNC and suggested that serum sFasL is consumed by binding to Fas expressed on activated circulating CD8+ T lymphocytes in patients with cancer, thereby reducing their sFasL levels compared to healthy controls [44].